214 related articles for article (PubMed ID: 21183681)
1. Improvement of dolichol-linked oligosaccharide biosynthesis by the squalene synthase inhibitor zaragozic acid.
Haeuptle MA; Welti M; Troxler H; Hülsmeier AJ; Imbach T; Hennet T
J Biol Chem; 2011 Feb; 286(8):6085-91. PubMed ID: 21183681
[TBL] [Abstract][Full Text] [Related]
2. Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7 alpha hydroxylase.
Ness GC; Zhao Z; Keller RK
Arch Biochem Biophys; 1994 Jun; 311(2):277-85. PubMed ID: 7911291
[TBL] [Abstract][Full Text] [Related]
3. Statins and the squalene synthase inhibitor zaragozic acid stimulate the non-amyloidogenic pathway of amyloid-beta protein precursor processing by suppression of cholesterol synthesis.
Kojro E; Füger P; Prinzen C; Kanarek AM; Rat D; Endres K; Fahrenholz F; Postina R
J Alzheimers Dis; 2010; 20(4):1215-31. PubMed ID: 20413873
[TBL] [Abstract][Full Text] [Related]
4. Genetic defects in dolichol metabolism.
Buczkowska A; Swiezewska E; Lefeber DJ
J Inherit Metab Dis; 2015 Jan; 38(1):157-69. PubMed ID: 25270028
[TBL] [Abstract][Full Text] [Related]
5. Identification of phosphorylated oligosaccharides in cells of patients with a congenital disorders of glycosylation (CDG-I).
Vleugels W; Duvet S; Peanne R; Mir AM; Cacan R; Michalski JC; Matthijs G; Foulquier F
Biochimie; 2011 May; 93(5):823-33. PubMed ID: 21315133
[TBL] [Abstract][Full Text] [Related]
6. Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase.
Bergstrom JD; Dufresne C; Bills GF; Nallin-Omstead M; Byrne K
Annu Rev Microbiol; 1995; 49():607-39. PubMed ID: 8561474
[TBL] [Abstract][Full Text] [Related]
7. Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A.
Vaidya S; Bostedor R; Kurtz MM; Bergstrom JD; Bansal VS
Arch Biochem Biophys; 1998 Jul; 355(1):84-92. PubMed ID: 9647670
[TBL] [Abstract][Full Text] [Related]
8. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase.
Bergstrom JD; Kurtz MM; Rew DJ; Amend AM; Karkas JD; Bostedor RG; Bansal VS; Dufresne C; VanMiddlesworth FL; Hensens OD
Proc Natl Acad Sci U S A; 1993 Jan; 90(1):80-4. PubMed ID: 8419946
[TBL] [Abstract][Full Text] [Related]
9. Congenital disorder of glycosylation due to DPM1 mutations presenting with dystroglycanopathy-type congenital muscular dystrophy.
Yang AC; Ng BG; Moore SA; Rush J; Waechter CJ; Raymond KM; Willer T; Campbell KP; Freeze HH; Mehta L
Mol Genet Metab; 2013 Nov; 110(3):345-351. PubMed ID: 23856421
[TBL] [Abstract][Full Text] [Related]
10. Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase.
Dufresne C; Wilson KE; Singh SB; Zink DL; Bergstrom JD; Rew D; Polishook JD; Meinz M; Huang L; Silverman KC
J Nat Prod; 1993 Nov; 56(11):1923-9. PubMed ID: 8289063
[TBL] [Abstract][Full Text] [Related]
11. Compensatory responses to inhibition of hepatic squalene synthase.
Lopez D; Chambers CM; Keller RK; Ness GC
Arch Biochem Biophys; 1998 Mar; 351(2):159-66. PubMed ID: 9514656
[TBL] [Abstract][Full Text] [Related]
12. Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type Ie.
Imbach T; Schenk B; Schollen E; Burda P; Stutz A; Grunewald S; Bailie NM; King MD; Jaeken J; Matthijs G; Berger EG; Aebi M; Hennet T
J Clin Invest; 2000 Jan; 105(2):233-9. PubMed ID: 10642602
[TBL] [Abstract][Full Text] [Related]
13. Regulation of dolichol-linked glycosylation.
Welti M
Glycoconj J; 2013 Jan; 30(1):51-6. PubMed ID: 22717794
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory activity to protein prenylation and antifungal activity of zaragozic acid D3, a potent inhibitor of squalene synthase produced by the fungus, Mollisia sp. SANK 10294.
Tanimoto T; Ohya S; Tsujita Y
J Antibiot (Tokyo); 1998 Apr; 51(4):428-31. PubMed ID: 9630865
[TBL] [Abstract][Full Text] [Related]
15. Dolichol phosphate mannose synthase (DPM1) mutations define congenital disorder of glycosylation Ie (CDG-Ie).
Kim S; Westphal V; Srikrishna G; Mehta DP; Peterson S; Filiano J; Karnes PS; Patterson MC; Freeze HH
J Clin Invest; 2000 Jan; 105(2):191-8. PubMed ID: 10642597
[TBL] [Abstract][Full Text] [Related]
16. A new intronic mutation in the DPM1 gene is associated with a milder form of CDG Ie in two French siblings.
Dancourt J; Vuillaumier-Barrot S; de Baulny HO; Sfaello I; Barnier A; le Bizec C; Dupre T; Durand G; Seta N; Moore SE
Pediatr Res; 2006 Jun; 59(6):835-9. PubMed ID: 16641202
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of squalene synthase but not squalene cyclase prevents mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis at a posttranscriptional level.
Peffley DM; Gayen AK
Arch Biochem Biophys; 1997 Jan; 337(2):251-60. PubMed ID: 9016820
[TBL] [Abstract][Full Text] [Related]
18. Photoidentification of mannosyltransferases of dolichol cycle in the mammary gland. Purification and characterization of GDP-Man:Man beta 1-->4GlcNAc beta 1-->4GlcNAc-P-P-dolichol mannosyltransferase.
Mudgapalli A; Roy SK; Holmes EH; Vijay IK
J Biol Chem; 1994 Apr; 269(15):11327-36. PubMed ID: 7512562
[TBL] [Abstract][Full Text] [Related]
19. Squalene synthase, a determinant of Raft-associated cholesterol and modulator of cancer cell proliferation.
Brusselmans K; Timmermans L; Van de Sande T; Van Veldhoven PP; Guan G; Shechter I; Claessens F; Verhoeven G; Swinnen JV
J Biol Chem; 2007 Jun; 282(26):18777-85. PubMed ID: 17483544
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
